W HEN DR. FIONA KOLIA launched Astoria Vision in 2004, she set out to deliver something the Rio Grande Valley had never seen before: an upscale boutique and optometric practice offering world-class ...

Alcon Inc. has received its first Food and Drug Administration approval since its spinoff from Swiss medical giant Novartis ...

Alcon posts steady growth in Vision Care and Surgical, with new drug and therapy launches ahead but execution risks persist.

The Global Intraocular Lens Market valued at US $3.9 billion in 2021 and is set to witness a growth rate of ~5-6% in the next 5 years. The global growth in cataract procedures driven by an aging ...

Alcon ALC recently received Food and Drug Administration (“FDA”) approval for its TRYPTYR (acoltremon ophthalmic solution) 0.003%. TRYPTYR is indicated for the treatment of the signs and symptoms of ...

intraocular lens (IOL), is now available on Alcon’s most advanced lens material—Clareon®.1 Clareon Vivity® received CE Mark and will commence commercial rollout in Europe from early Q2 2025.

GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Vivity ® , the most widely implanted 9 extended depth ...

Alcon’s ALC Surgical business continues to gain from its diverse portfolio and incremental innovation. Within Vision Care, the company is registering solid growth, banking on strong sales of its ...

For instance, Alcon Inc. stated in January 2024 that the AcrySof IQ VivityTM IOL (Vivity), a cutting-edge intraocular lens with increased depth of focus, would be commercially available in the ...

For instance, Alcon Inc. stated in January 2024 that the AcrySof IQ VivityTM IOL (Vivity), a cutting-edge intraocular lens with increased depth of focus, would be commercially available in the United ...